Literature DB >> 11371191

Binding of plasminogen and tissue plasminogen activator to plasmin-modulated factor X and factor Xa.

J E Grundy1, N Lavigne, T Hirama, C R MacKenzie, E L Pryzdial.   

Abstract

Previous work in our laboratory has suggested that the fibrinolytic enzyme plasmin (Pn) inactivates coagulation factors X (FX) and Xa (FXa) in the presence of Ca(2+) and anionic phospholipid (aPL), producing fragments which bind plasminogen (Pg) and accelerate tissue plasminogen activator (t-PA). Our goals here were to determine if the Pn-mediated fragments of FX or FXa remain associated, whether they directly bind t-PA, and to quantify their interaction with Pg. Binding to aPL, benzamidine-Sepharose, or the active-site inhibitor dansyl-Glu-Gly-Arg-chloromethyl ketone demonstrated that Pn cleavage yielded noncovalent heterodimers of a fragment containing the aPL-binding domain (FXgamma(47) or FXagamma(33)) and a 13-kDa fragment (FXgamma(13) or FXagamma(13)). Both ligand blotting and surface plasmon resonance (SPR) showed that Pn-cleaved FX and FXa bound t-PA directly when Pn-treatment was effected in the presence of aPL and Ca(2+). Using SPR, apparent K(d) values of 1-3 microM and 0.3-0.4 microM were measured directly and by competition for the FXgamma(47/13)-Pg and FXagamma(33/13)-Pg interactions, respectively. For the first time, Pg-binding to a receptor was shown to be Ca(2+) enhanced, although primarily mediated by C-terminal lysine residues. Mathematical modeling of kinetic data suggesting two Pg per FXgamma(47/13) or FXagamma(33/13) was consistent with our conclusion that each subunit of FXgamma(47/13) or FXagamma(33/13) contains a C-terminal lysine. Earlier X-ray structures show that these Lys residues are distal from each other and the membrane, supporting the model where each interacts with a separate Pg. t-PA acceleration by FXgamma(47/13) or FXagamma(33/13) may therefore involve simultaneous presentation of two substrate molecules.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11371191     DOI: 10.1021/bi002209v

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Thrombolysis by chemically modified coagulation factor Xa.

Authors:  E L G Pryzdial; S C Meixner; K Talbot; L J Eltringham-Smith; J R Baylis; F M H Lee; C J Kastrup; W P Sheffield
Journal:  J Thromb Haemost       Date:  2016-08-17       Impact factor: 5.824

2.  Plasmin-mediated proteolysis of human factor IXa in the presence of calcium/phospholipid: Conversion of procoagulant factor IXa to a fibrinolytic enhancer.

Authors:  Amy E Schmidt; Kanagasabai Vadivel; Julian Whitelegge; Satya Paul Bajaj
Journal:  J Thromb Haemost       Date:  2020-03-30       Impact factor: 5.824

3.  Incidence of residual perfusion defects by lung scintigraphy in patients treated with rivaroxaban compared with warfarin for acute pulmonary embolism.

Authors:  Ming Sheng Lim; Dee Nandurkar; Ian Jong; Anita Cummins; Huyen Tran; Sanjeev Chunilal
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

4.  Does plasmin have anticoagulant activity?

Authors:  Jane Hoover-Plow
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

5.  Coagulation factor Va Glu-96-Asp-111: a chelator-sensitive site involved in function and subunit association.

Authors:  Abed R Zeibdawi; Jean E Grundy; Bogna Lasia; Edward L G Pryzdial
Journal:  Biochem J       Date:  2004-01-01       Impact factor: 3.857

6.  Coagulation and fibrinolytic features in AL amyloidosis with abnormal bleeding and usefulness of tranexamic acid.

Authors:  Masahisa Arahata; Hiroyuki Takamatsu; Eriko Morishita; Yasuko Kadohira; Shinya Yamada; Akitada Ichinose; Hidesaku Asakura
Journal:  Int J Hematol       Date:  2020-01-03       Impact factor: 2.490

7.  Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency.

Authors:  Joline L Saes; Saskia E M Schols; Kathleen F Betbadal; Mark van Geffen; Kitty Verbeek-Knobbe; Sweta Gupta; Brandon M Hardesty; Amy D Shapiro; Waander L van Heerde
Journal:  Haemophilia       Date:  2019-08-30       Impact factor: 4.287

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.